Trinka, Eugen http://orcid.org/0000-0002-5950-2692
Lattanzi, Simona
Carpenter, Kate
Corradetti, Tommaso
Nucera, Bruna
Rinaldi, Fabrizio
Shankar, Rohit
Brigo, Francesco
Funding for this research was provided by:
Paracelsus Medical University
Article History
Accepted: 22 May 2021
First Online: 7 July 2021
Declarations
:
: Open access funding was provided by Paracelsus Medical University. Eisai Inc. provided funding for medical writing support, which was provided by Kate Carpenter and Roseanne Wilkinson, and for librarian support in conducting literature searches.
: BN, FB, FR, TC have nothing to disclose. ET has nothing to disclose related to the submitted work. Outside the submitted work, ET has received consultancy fees from Arvelle, Argenix, Clexio, Celegene, UCB, Eisai, Epilog, Bial, Medtronic, Everpharma, Biogen, Takeda, Liva-Nova, Newbridge, Sunovion, GW Pharmaceuticals and Marinus; speaker fees from Arvelle, Bial, Biogen, Böhringer Ingelheim, Eisai, Everpharma, GSK, GW Pharmaceuticals, Hikma, Liva-Nova, Newbridge, Novartis, Sanofi, Sandoz and UCB; research funding (directly, or to his institution) from GSK, Biogen, Eisai, Novartis, Red Bull, Bayer and UCB. ET receives grants from Austrian Science Fund (FWF), Österreichische Nationalbank, and the European Union. ET is the CEO of Neuroconsult Ges.m.b.H. SL has nothing to disclose related to the submitted work. Outside the submitted work, SL has received speaker or consultancy fees from Eisai, UCB Pharma and GW Pharmaceuticals and has served on advisory boards for GW Pharmaceuticals and Arvelle Therapeutics. KC received financial support from Eisai Inc. for writing work on this manuscript, and has received fees from Eisai for other writing and consultancy work unrelated to this manuscript. RS has nothing to disclose related to the submitted work. Outside the submitted work, RS reports institutional research grants and fees from LivaNova, Eisai, Bial, UCB, Desitin, Averelle and GW pharma, and is a stakeholder in epilepsy checklists and monitoring systems.
: Not applicable.
: Not applicable.
: Not applicable.
: We have made all data that were extracted for this manuscript available in the electronic supplementary material (Supplemental Table S1)
: Not applicable.
: ET initiated the project. ET, SL FB, RS and KC developed the protocol. FB, BN, RW and FR manually searched conference abstract databases. FB, BN and FR screened retrieved abstracts. FB, BN and FR manually reviewed reference lists of retrieved article for additional reports. KC manually searched clinical trial databases and screened for relevance. SL and TC reviewed full texts for selection/exclusion. KC and RW checked screening and selection. ET made decisions on inclusion where reviewers disagreed. RS conducted risk of bias assessment. RW extracted data from selected reports. KC checked data extraction. All authors reviewed the outline. KC and RW prepared tables. KC drafted the Methods and Results sections. ET and SL drafted the Introduction and Discussion. All authors reviewed and provided intellectual contributions to the draft manuscript. All authors approved the final draft.